Better Coronavirus Stock: Johnson & Johnson vs. Novavax
Two very different drugmakers have recently joined the elite group of companies with coronavirus vaccines in late-stage testing. Johnson & Johnson (NYSE: JNJ) initiated a global phase 3 clinical study of JNJ-78436735 (also known as Ad26.COV2.S) on Sept. 23. Novavax (NASDAQ: NVAX) started a phase 3 test of its COVID-19 vaccine candidate in the U.K. the following day.
Novavax has been the bigger winner so far this year. But which of these coronavirus stocks is the better pick now?
Image source: Getty Images.
Source Fool.com
